345 related articles for article (PubMed ID: 35371055)
1. Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy.
Gao R; Shi GP; Wang J
Front Immunol; 2022; 13():833667. PubMed ID: 35371055
[TBL] [Abstract][Full Text] [Related]
2. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
3. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
4. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
5. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
6. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
Nishikawa H; Koyama S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
Liu J; Zhang B; Zhang G; Shang D
Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
[TBL] [Abstract][Full Text] [Related]
9. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
10. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells.
Beauford SS; Kumari A; Garnett-Benson C
BMC Immunol; 2020 Apr; 21(1):18. PubMed ID: 32299365
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting or reprogramming of intra-tumoral Tregs.
Mortezaee K
Med Oncol; 2024 Feb; 41(3):71. PubMed ID: 38341821
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.
Tay C; Tanaka A; Sakaguchi S
Cancer Cell; 2023 Mar; 41(3):450-465. PubMed ID: 36917950
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.
Chung DJ; Rossi M; Romano E; Ghith J; Yuan J; Munn DH; Young JW
Blood; 2009 Jul; 114(3):555-63. PubMed ID: 19465693
[TBL] [Abstract][Full Text] [Related]
15. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer.
Fattori S; Roux H; Connen E; Robert L; Gorvel L; Le Roy A; Houacine J; Foussat A; Chretien AS; Olive D
Cancer Res; 2022 Nov; 82(21):3868-3879. PubMed ID: 36040356
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
19. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor-related immunosuppression for cancer immunotherapy.
Frumento G; Piazza T; Di Carlo E; Ferrini S
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):233-7. PubMed ID: 17017974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
